Vontobel Holding Ltd. Arcutis Biotherapeutics, Inc. Transaction History

Vontobel Holding Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jun 03, 2024	SELL	$1.84 - $4.82 $51,871 - $135,880	-28,191 Reduced 57.31%	21,000 $67,000
Q4 2023 Jan 29, 2024	SELL	$1.84 - $4.82 $51,871 - $135,880	-28,191 Reduced 57.31%	21,000 $67,000
Q3 2023 Jun 03, 2024	BUY	$5.31 - $10.98 $112,173 - $231,952	21,125 Added 75.27%	49,191 $261,000
Q3 2023 Oct 10, 2023	BUY	$5.31 - $10.98 $112,173 - $231,952	21,125 Added 75.27%	49,191 $261,000
Q2 2023 Jun 03, 2024	BUY	$7.51 - $15.0 $39,893 - $79,680	5,312 Added 23.35%	28,066 $267,000
Q2 2023 Jul 24, 2023	BUY	$7.51 - $15.0 $39,893 - $79,680	5,312 Added 23.35%	28,066 $267,000
Q1 2023 Jun 03, 2024	BUY	$10.23 - $17.14 $17,943 - $30,063	1,754 Added 8.35%	22,754 $250,000
Q1 2023 Apr 12, 2023	BUY	$10.23 - $17.14 $24,255 - $40,638	2,371 Added 11.63%	22,754 $250,000
Q4 2022 Feb 14, 2023	BUY	$13.96 - $20.4 $137,743 - $201,286	9,867 Added 93.83%	20,383 $301,000
Q3 2022 Nov 04, 2022	BUY	$17.85 - $26.95 $187,710 - $283,406	10,516 New	10,516 $201,000

197

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $568M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

Stay updated on Vontobel Holding Ltd. with notifications on news.